Recursion Pharmaceuticals, Inc., a Delaware-incorporated company trading under the symbol RXRX on the Nasdaq Global Select Market, has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. The report follows up on a previously disclosed transaction agreement dated August 8, 2024, between Recursion Pharmaceuticals and Exscientia plc. The agreement outlines Recursion's plan to acquire all issued and to be issued share capital of Exscientia through a scheme of arrangement under the UK Companies Act 2006, pending approval from both companies' shareholders. In support of this transaction, shareholders of Exscientia holding approximately 42% of its share capital had already entered into irrevocable undertakings to vote in favor of the transaction. Additionally, Evotec SE, holding...Show More

Recursion Pharmaceuticals, Inc., a Delaware-incorporated company trading under the symbol RXRX on the Nasdaq Global Select Market, has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. The report follows up on a previously disclosed transaction agreement dated August 8, 2024, between Recursion Pharmaceuticals and Exscientia plc. The agreement outlines Recursion's plan to acquire all issued and to be issued share capital of Exscientia through a scheme of arrangement under the UK Companies Act 2006, pending approval from both companies' shareholders. In support of this transaction, shareholders of Exscientia holding approximately 42% of its share capital had already entered into irrevocable undertakings to vote in favor of the transaction. Additionally, Evotec SE, holding about 11% of Exscientia's share capital, has also agreed to vote in favor through a similar irrevocable undertaking. Collectively, these shareholders control approximately 53% of Exscientia's share capital. The report also mentions that a joint proxy statement will be filed with the SEC, providing full details of the proposed transaction. The communication is not an offer to sell securities but is intended to inform shareholders about the upcoming proxy statement and the proposed transaction.